Ruxolitinib, wanda kuma aka sani da ruxolitinib a kasar Sin, yana daya daga cikin "sabbin magunguna" da aka jera a ko'ina cikin jagororin asibiti don maganin cututtukan hematological a cikin 'yan shekarun nan, kuma ya nuna tasiri mai tasiri a cikin cututtuka na myeloproliferative.
Maganin da aka yi niyya Jakavi ruxolitinib na iya hana kunna duk tashar JAK-STAT yadda yakamata kuma ya rage siginar da aka inganta ta hanyar da ba ta dace ba, don haka samun inganci.Hakanan za'a iya amfani dashi don maganin cututtuka iri-iri, da kuma rashin daidaituwa na shafin JAK1.
Ruxolitinibshine mai hana kinase wanda aka nuna don kula da marasa lafiya tare da matsakaici ko babban haɗari na myelofibrosis, ciki har da myelofibrosis na farko, post-geniculocytosis myelofibrosis, da kuma post-primary thrombocythemia myelofibrosis.
Irin wannan binciken na asibiti (n = 219) marasa lafiya marasa lafiya tare da matsakaici-haɗari-2 ko babban haɗari na farko MF, marasa lafiya tare da MF bayan erythroblastosis na gaskiya, ko marasa lafiya tare da MF bayan thrombocytosis na farko zuwa ƙungiyoyi biyu, wanda ke karɓar ruxolitinib na baka 15 zuwa 20 mgbid. (n=146) da sauran suna karɓar ingantaccen magani mai kulawa (n=73).Na farko da kuma manyan sakandare na binciken sune adadin marasa lafiya da ≥35% a cikin ƙaƙƙarfan murfi ko harhada maganganun maganganu) makonni 48 da 24, bi da bi.Sakamakon ya nuna cewa yawan marasa lafiya tare da fiye da 35% raguwa a cikin ƙwayar ƙwayar cuta daga asali a mako 24 shine 31.9% a cikin ƙungiyar kulawa idan aka kwatanta da 0% a cikin ƙungiyar kulawa (P <0.0001);da yawan marasa lafiya tare da fiye da 35% raguwa a cikin ƙwayar ƙwayar cuta daga asali a mako 48 shine 28.5% a cikin ƙungiyar kulawa idan aka kwatanta da 0% a cikin ƙungiyar kulawa (P <0.0001).Bugu da ƙari, ruxolitinib kuma ya rage yawan bayyanar cututtuka kuma ya inganta ingantaccen rayuwa a cikin marasa lafiya.Dangane da sakamakon waɗannan gwaje-gwajen asibiti guda biyu,ruxolitinibya zama magani na farko da FDA ta Amurka ta amince don kula da marasa lafiya tare da MF.